3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gastric neoplasm, neoplasm, stomach disorderActive, not recruitingPhase 32026-09-28NCT03653507
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerNeoplasms by Histologic Type, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasmRecruitingPhase 32026-09-24NCT06901531
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerNeoplasms by Histologic Type, adenocarcinoma, carcinoma, epithelial neoplasm, gastric adenocarcinoma, neoplasm, pancreatic adenocarcinomaRecruitingPhase 12026-09-11NCT05365581